ReviewJournal of translational medicine2026
HER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesis and therapeutic resistance.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman epidermal growth factor receptor 3 (HER3/ErbB3) is classically recognized as a kinase-impaired member of the epidermal growth factor receptor (EGFR) family, which can initiate oncogenic signaling by heterodimerizing with family members. However, the emerging drug resistance issues of HER-targeted therapies emerges have urged researchers to decipher the role of HER3 as a versatile signaling hub, which is beyond its canonical paradigm. MAIN BODY: This review delineated the non-canonical landscape of HER3, providing a specialized dissection of its roles which distinguished from the general overviews. We summarized the non-EGFR family heterodimerization partners for HER3 (e.g. MET, FGFR, and IGF1R) and its unique role as a transcriptional co-regulator in the nucleus, and discussed the clinical conundrum regarding its divergent prognostic roles in different cancer types. By integrating the cutting-edge findings in recent years, this review presented the pivotal role of tumor cells hijacking HER3 to achieve metabolic reprogramming and the regulation of tumor microenvironment. These non-canonical mechanisms of HER3 collectively contribute to the adaptive resistance to radiotherapy, chemotherapy, and immunotherapy.
conclusionsBy integrating current insights and analyzing unresolved paradoxes in published data, this review elaborated the versatile roles of HER3, and constructed a novel theoretical framework to lay foundation for conquering the challenges of therapeutic resistance in precision oncology by developing next-generation HER3-targeted strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.